NCT00426296

Brief Summary

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 23, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 24, 2007

Completed
Last Updated

November 1, 2007

Status Verified

October 1, 2007

First QC Date

January 23, 2007

Last Update Submit

October 30, 2007

Conditions

HIV InfectionsLipodystrophy

Keywords

HIVReyatazatazanavirNorvirritonavirBoostedLipodystrophyTreatment Experienced

Interventions

atazanavir (Reyataz)DRUG
ritonavir (Norvir)DRUG

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
  • Viral load \<50 copies/ml

You may not qualify if:

  • Viral load \>50 copies/ml
  • Having taken more than one antiretroviral regimen

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Whitman-Walker Clinic

Washington D.C., District of Columbia, United States

RECRUITING

MeSH Terms

Conditions

HIV InfectionsLipodystrophy

Interventions

Atazanavir SulfateRitonavir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSkin Diseases, MetabolicSkin DiseasesSkin and Connective Tissue DiseasesLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

PyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsOligopeptidesPeptidesAmino Acids, Peptides, and ProteinsThiazolesSulfur CompoundsOrganic ChemicalsAzoles

Study Officials

  • Richard A Elion, MD

    Whitman-Walker Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Richard A. Elion, MD

CONTACT

drrelion@aol.com

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 23, 2007

First Posted

January 24, 2007

Study Start

August 1, 2006

Last Updated

November 1, 2007

Record last verified: 2007-10

Locations

US(1)